Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE versus TARACTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE versus TARACTAN.
FLUPHENAZINE vs TARACTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with high potency and additional antagonism at alpha-adrenergic, muscarinic, and histaminergic receptors.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Fluphenazine decanoate (long-acting): 12.5-25 mg IM every 2 weeks; Fluphenazine hydrochloride (oral): 2.5-10 mg daily in divided doses; initial titration 2.5-10 mg/day, maintenance 1-5 mg/day. Maximum oral dose 20 mg/day.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
None Documented
None Documented
Clinical Note
moderateFluphenazine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Fluticasone propionate."
Clinical Note
moderateFluphenazine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Fluphenazine."
Clinical Note
moderateFluphenazine + Methylphenidate
"The risk or severity of adverse effects can be increased when Fluphenazine is combined with Methylphenidate."
Clinical Note
moderateTerminal elimination half-life is 15-30 hours, but may extend to 40-50 hours after chronic use; clinical context: dosing interval is typically 12-24 hours, and steady-state is reached within 3-5 days.
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Primarily hepatic metabolism with biliary excretion. Less than 1% excreted unchanged in urine; fecal elimination accounts for approximately 20-30% of metabolites.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Category A/B
Category C
Typical Antipsychotic
Typical Antipsychotic
Fluphenazine + Quinagolide
"The therapeutic efficacy of Quinagolide can be decreased when used in combination with Fluphenazine."